SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending after reporting substantial revenue growth and positive adjusted EBITDA, coupled with increased capacity guidance and the strategic acquisition of AI agentic search company Tavily. The community is actively debating whether these strong operational metrics and strategic moves outweigh a perceived earnings miss, positioning NBIS as a highly discussed AI infrastructure play amid intense sector demand.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as its oral obesity drug VK2735 received FDA clearance to skip a trial phase and advance directly into Phase 3, significantly accelerating its development timeline in the competitive GLP-1 market. This strategic acceleration, coupled with promising data from its injectable program and recent regulatory actions against compounded alternatives, has fueled community discussions about potential partnerships or a significant short squeeze, despite recent mixed financial results.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape's new Eagle Line pilot production facility and ongoing B-sample shipments to automotive OEMs are sparking intense community discussion. Investors are actively debating the company's path to commercialization and eagerly anticipating concrete partnership announcements for its solid-state battery technology.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following the U.S. FDA approval of its Optune Pax, a Tumor Treating Fields therapy for locally advanced pancreatic cancer, hailed as the first new treatment in three decades with improved patient outcomes. The community is actively debating significant upside potential from this groundbreaking news, while some caution about previous stock volatility and potential commercial challenges, despite promising survival and pain progression data from trials.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly (FSLY) is surging after reporting record Q4 and full-year 2025 financial results, achieving significant revenue growth, improved gross margins, and a return to profitability, alongside an optimistic 2026 outlook. The community is highlighting the company's turnaround, citing strong security revenue and AI-driven tailwinds as key growth drivers, with many believing the stock remains undervalued despite the sharp move.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending due to the impending shareholder vote to merge with Infleqtion, a quantum technology leader that recently secured high-profile contracts with NASA for space sensing and the U.S. Department of Energy for energy grid optimization. The community is actively debating Infleqtion's significant undervaluation compared to its peers and its robust real-world applications, though some express caution given the SPAC sponsor's past performance.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is trending following an unexpected adjusted earnings and revenue beat, defying earlier market pessimism and driving a significant rally. Community sentiment highlights the stock's perceived undervaluation, ongoing share buybacks, and signs of stabilization in its HeyDude brand as key drivers, despite broader sector headwinds.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is trending following its strong Q4 earnings, beat-and-raise guidance, and new $1 billion share buyback, yet the stock is experiencing a sharp sell-off, prompting intense community debate over whether analyst price target cuts and pervasive "AI disruption" fears are unjustly punishing the SaaS sector.

MNDE is the governance token for Marinade. Marinade helps you to stake Solana without locking in liquidity by turning SOL into mSOL - tokenized version of staked SOL. This way you can both secure the network by staking SOL, and use your mSOL as the ultimate unit in Solana DeFi ecosystem. To provide liquidity, deposit in lending protocols and even buy NFTs.

Marinade

Marinade (MNDE) is trending as the community widely discusses its significant undervaluation, highlighting its substantial Total Value Locked (TVL) on the Solana blockchain relative to its market capitalization, positioning it as a leading liquid staking platform poised for a potential breakout.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending amid mixed Q4 earnings and cautious Q1 guidance, sparking frustration among investors over consistent 'fluff' from management. However, community discussions are intensifying around the company's crucial role in next-generation Co-Packaged Optics (CPO) for AI data centers, with many anticipating a significant revenue ramp in the coming years despite current subdued outlooks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of <a href="https://stocktwits.com/symbol/ATHE">Alterity Therapeutics</a> soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average.The clinical-stage biotech announced positive Phase 2 results for ATH434, its oral treatment for early-stage multiple system atrophy (MSA)— a rare neurodegenerative disease.Key findings from the 52-week trial:<ul style="list-style-type:square;"><li>50 mg dose: 48% reduction in clinical progression vs. placebo</li><li>75 mg dose: 29% reduction in clinical progression vs. placebo</li></ul>The 50 mg dose reduced iron accumulation in multiple system atrophy-affected brain regions, while the 75 mg dose specifically reduced iron buildup in the globus pallidus.CEO David Stamler said, “Currently, there are no approved treatments that slow the progression of MSA, and these results show ATH434’s targeted iron engagement may truly have a disease-modifying effect.”<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATHE_sentiment_and_message_volume_Jan_30_premarket_df297a4b9a.png" alt="ATHE sentiment and message volume Jan 30 premarket.png" width="1318" height="324"><figcaption>ATHE sentiment and message volume Jan 30 premarket as of 9 am ET | source: Stocktwits</figcaption></figure>Stocktwits message volume for Alterity skyrocketed, hitting ‘extremely high’ levels ahead of Thursday’s&nbsp;opening bell, with sentiment hitting the highest reading in over a year.Some users predicted ATHE could more than triple, stabilizing around $10, while others reiterated their bullish stance on the drug’s market potential.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/602113870</stembedurl><stembedurl>https://stocktwits.com/DaBullRunner/message/602113078</stembedurl>ATHE was among the top three trending tickers on Stocktwits early Thursday.&nbsp;Message volume around the stock on the platform has surged 700% over the past year, during which it has gained 46%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Equity

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

ATHE
Alterity Therapeutics Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ATHE News

ATHEAlterity Therapeutics Ltd - ADR